drugset
drugset / Trial / NCT05632393

A Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women

NCT05632393 ↗

Phase 1 Completed 10 enrolled Idorsia Pharmaceuticals Ltd.
NaSingle-groupOpen-labelOther

Summary

A study to measure daridorexant in breast milk of healthy lactating women

Timeline

Start
2023-01-16
Primary completion
2023-04-30
Completion
2023-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Daridorexant Small molecule 50 mg Oral

Indications

No indication recorded.